The Medical Letter on Drugs and Therapeutics
Influenza Vaccine for 2011-2012
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Annual vaccination against influenza A and B viruses is the most effective method of preventing influenza and has been shown to decrease influenza illness and complications. For the current season, a new inactivated intradermal vaccine (Fluzone Intradermal) has been FDA-approved for use in adults 18-64 years old. An upcoming issue will review chemoprophylaxis and treatment of influenza.

VACCINE COMPOSITION 2011-2012 — This year’s seasonal trivalent influenza vaccine contains the same three strains as the 2010-2011 formulation: A/California/7/2009 H1N1-like (derived from the pandemic 2009 influenza virus), A/Perth/16/2009 H3N2-like, and B/Brisbane/60/2008-like1.

WHO SHOULD BE VACCINATED — The Advisory Committee for Immunization Practices (ACIP) recommends annual influenza vaccination for everyone ≥6 months old, including pregnant women, without ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Influenza Vaccine for 2011-2012
Article code: 1375a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian